Diabetes drug semaglutide put to the test in chilean patients
NCT ID NCT05533632
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This completed study tested the safety and tolerability of a once-weekly injection of semaglutide (0.5 or 1.0 mg) in 104 Chilean adults with type 2 diabetes. Participants received the drug for 24 weeks, with regular blood and urine tests. The main goal was to count any side effects, while also tracking changes in blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Padre Hurtado
Santiago, Región Metropolitana, 8880465, Chile
-
Hospital San Juan de Dios_Santiago, Región Metropolitana
Santiago, Región Metropolitana, 8350429, Chile
-
Servicios Médicos Godoy Limitada
Santiago, Región Metropolitana, 7500710, Chile
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (a once-weekly injection for diabetes)
What this could lead to
If successful, this study could confirm that semaglutide is safe and well-tolerated for managing type 2 diabetes in Chilean patients.
What could go wrong
This is a small, completed Phase 4 safety study, not designed to prove long-term benefits or cure. Side effects like nausea or rare risks may still occur.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.